Q-omics provides the consensus-scored SMR3B profile across patient tissues and cancer cell-line models. SMR3B expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, SMR3B is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, SMR3B RNA expression shows 6,324 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight DLBC, HNSC, and STAD as cancer lineages where SMR3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMR3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMR3B survival associations across molecular data types. SMR3B RNA expression shows survival associations in the most cancer types (9), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMR3B RNA expression–survival associations across cancer types. High SMR3B expression shows unfavorable associations in DLBC, READ, SCLC, LUAD and LGG, but favorable associations in GBM. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify DLBC as the clearest survival context for SMR3B RNA expression.
This table summarizes SMR3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 1. The strongest signals are observed in BRCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SMR3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMR3B shows lower tumor expression in HNSC, BRCA, PRAD and THCA and higher tumor expression in UCEC. The HNSC box plot shows higher SMR3B RNA expression in normal versus tumor tissue (log2 FC = −3.807, t-test p < 0.001).
This table shows molecular features associated with SMR3B in patient tissues and cancer cell lines. In patient samples, SMR3B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SMR3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
